Target type: biologicalprocess
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of phosphate. [GOC:jl]
Cellular response to phosphate starvation is a complex and tightly regulated process that involves a series of molecular events to ensure cellular survival and maintain essential phosphate homeostasis in the face of limited phosphate availability. Phosphate is a critical component of various cellular processes, including energy metabolism, DNA and RNA synthesis, and signal transduction. When phosphate levels drop below a critical threshold, cells initiate a cascade of responses to conserve existing phosphate, acquire new phosphate from the environment, and adapt to phosphate limitation.
The first line of defense involves **phosphate scavenging** and **recycling**. Cells activate phosphate transporters to uptake any remaining phosphate from the environment. Intracellular phosphate is also recycled from existing cellular components like phospholipids and proteins. This process is regulated by specific phosphatases and kinases that control the phosphorylation state of key proteins involved in phosphate metabolism.
Simultaneously, cells **reduce phosphate consumption**. This involves downregulating energy-consuming processes like protein synthesis and cell growth. Cells also activate alternative pathways for energy production that require less phosphate.
If phosphate depletion persists, cells activate a **phosphate-responsive transcription factor (PHR1)**. PHR1 triggers the expression of genes encoding high-affinity phosphate transporters, phosphatases, and enzymes involved in phosphate metabolism. These genes are often found in clusters regulated by phosphate-responsive promoters.
In addition to the transcriptional changes, cells can also alter their **cell morphology and physiology** to increase phosphate uptake. This might include changes in root architecture in plants, or the production of extracellular vesicles in animals.
The cellular response to phosphate starvation is a crucial survival mechanism. It allows cells to cope with nutrient limitation by re-allocating resources, enhancing phosphate acquisition, and minimizing phosphate loss. This intricate network of responses ensures cellular homeostasis and survival during periods of phosphate stress.'
"
Protein | Definition | Taxonomy |
---|---|---|
Catechol O-methyltransferase | A catechol O-methyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P21964] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
oxyquinoline | Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes. | monohydroxyquinoline | antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator |
verapamil | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine. Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent. | aromatic ether; nitrile; polyether; tertiary amino compound | |
8-hydroxyquinoline-5-sulfonic acid | 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd | ||
5'-methylthioadenosine | 5'-methylthioadenosine: structure 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group. | thioadenosine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
sitagliptin | sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity. | triazolopyrazine; trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic |
tolcapone | tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated. | 2-nitrophenols; benzophenones; catechols | antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor |
entacapone | entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. entacapone: structure given in first source | 2-nitrophenols; catechols; monocarboxylic acid amide; nitrile | antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor |
opicapone | opicapone: structure in first source | oxadiazole; ring assembly |